眼科疾患治療薬の世界市場規模調査・予測、薬物クラス別・投与量別・適応疾患別・流通チャネル別・地域別分析、2022-2029年

眼科疾患治療薬の世界市場は、2021年に約315億4,000万米ドルと評価され、予測期間2022-2029年には6.4%以上の健全な成長率で成長すると予測されています。

緑内障、ドライアイ、網膜疾患など、さまざまな眼科疾患を治療するための薬剤や治療薬は、眼科疾患治療薬に含まれます。眼科疾患治療薬市場は、眼科疾患の有病率の上昇、革新的な医薬品や治療薬の臨床試験やパイプライン候補の増加などの要因によって拡大しています。

世界的には、緑内障、網膜疾患、ドライアイ疾患などの眼科疾患の有病率が上昇傾向にあり、これが市場成長のケータリングとなっています。米国眼科学会（AAO）の2020年の記事によると、米国では300万人（うち40歳以上が270万人）が緑内障に罹患しているとされています。世界銀行グループによると、世界の高齢者人口は2020年に7億2,700万人で、今後30年で3倍に増え、2050年には15億人に達すると予測されています。様々なヘルスケア機関、政府機関、業界関係者による取り組みが増え、国民の間で眼疾患に対する意識が高まり、医療費の増大や先進国・発展途上国の双方における眼科医の増加などの要因により、眼疾患の治療に対する市場需要が高まると予想されます。ウェールズ政府の2021年報告書によると、ウェールズにおける眼科開業医の数は、2020年3月の885人から2021年3月には961人に上昇しました。しかし、眼科疾患治療薬の高コストが、2022-2029年の予測期間を通じて市場の成長を阻害しています。

Ophthalmic Disease Therapeuticsの世界市場調査において考慮された主要地域は、アジア太平洋地域、北米、欧州、中南米、その他世界のその他の地域です。北米は、診断と治療の割合の増加、および多くの眼疾患の有病率の増加により、収益の面で市場を独占しています。また、同地域では、アイケアや目の健康を支えるヘルスケア支出が増加しており、さまざまな眼疾患に対する補償も充実していることから、同地域の主要国では、最先端かつ新規の治療法の導入が進んでいます。一方、欧州は予測期間中に最も高いCAGRで成長すると予想されています。これは、老年人口および対象人口の増加、製品開発のための共同研究の増加、主要企業の地域的拡大、政府および非営利団体の市場参入の積極化などの要因に起因しています。

本調査の目的は、近年におけるさまざまなセグメント＆国の市場規模を定義し、今後数年間の値を予測することです。本レポートは、調査対象国の産業の質的・量的な側面を取り入れるよう設計されています。

また、市場の将来的な成長を規定する促進要因や課題など、重要な側面に関する詳細情報も提供しています。さらに、主要企業の競合情勢や競合情勢の詳細な分析とともに、利害関係者が投資するためのミクロ市場での潜在的な機会も組み込んでいます。

目次

第1章 エグゼクティブサマリー

• 市場スナップショット
• 世界・セグメント別市場推定・予測、2019年～2029年
  • 眼科疾患治療薬市場、地域別、2019-2029年
  • 眼科疾患治療薬市場、薬効クラス別、2019-2029年
  • 眼科疾患治療薬の市場（投与量から）：2019年～2029年
  • 眼科疾患治療薬市場、疾患適応症別、2019-2029年
  • 眼科疾患治療薬市場、流通チャネル別、2019-2029年
• 主な動向
• 調査手法
• 調査の前提条件

第2章 眼科疾患治療薬の世界市場の定義と範囲

• 調査目的
• 市場の定義と範囲
  • 調査対象範囲
  • 産業の進化
• 本調査の対象となった年
• 通貨換算レート

第3章 眼科疾患治療薬の世界市場力学

• 眼科疾患治療薬市場の影響分析（2019年～2029年）
  • 市場促進要因
    • 眼科疾患の有病率の上昇
    • 革新的な医薬品・治療薬の臨床試験とパイプライン候補の増加
  • 市場の課題
    • 生物学的製剤の高額な費用と治療費全般について
  • 市場機会
    • ドラッグデリバリーに関する技術的進歩の高まり
    • 個別化医療の進展の高まり

第4章 眼科疾患治療薬の世界市場：産業分析

• ポーターの5フォースモデル
  • 供給企業の交渉力
  • 買い手の交渉力
  • 新規参入業者の脅威
  • 代替品の脅威
  • 競争企業間の敵対関係
• ポーターの5フォースモデルへの未来的アプローチ（2019-2029年）
• PEST分析
  • 政治的
  • 経済的
  • ソーシャル
  • テクニカル
• 主な投資機会
• 主要成功戦略
• 業界関係者見通し
• アナリストの提言と結論

第5章 リスク評価：COVID-19の影響

• COVID-19が業界に与える全体的な影響についての評価
• COVID-19以前とCOVID-19以後の市場シナリオ

第6章 眼科疾患治療薬の世界市場：薬物クラス別

• 市場スナップショット
• 眼科疾患治療薬の世界市場：薬物クラス別）、実績 - ポテンシャル分析
• 眼科疾患治療薬の世界市場薬剤クラス別推定・予測2019-2029
• 眼科疾患治療薬市場、サブセグメント分析
  • 抗炎症作用
  • アンチインベーティブ
  • 抗VEGF薬
  • その他

第7章 眼科疾患治療薬の世界市場：投与量別

• 市場スナップショット
• 眼科疾患治療薬の世界市場：投与量別、業績別- ポテンシャル分析
• 眼科疾患治療薬の世界市場推定・予測（用量別）2019-2029年まで
• 眼科疾患治療薬市場、サブセグメント分析
  • ソリッド
  • リキッド
  • 半固体

第8章 眼科疾患治療薬の世界市場：適応疾患別

• 市場スナップショット
• 眼科疾患治療薬の世界市場：適応疾患別、業績-ポテンシャル分析
• 眼科疾患治療薬の世界市場疾患別推定・予測2019-2029
• 眼科疾患治療薬市場、サブセグメント分析
  • 緑内障
  • ドライアイ疾患
  • 網膜疾患
  • アレルギー・感染症
  • その他

第9章 眼科疾患治療薬の世界市場：流通チャネル別

• 市場スナップショット
• 眼科疾患治療薬の世界市場：流通チャネル別、実績 - ポテンシャル分析
• 眼科疾患治療薬の世界市場推計・予測（流通チャネル別） 2019-2029
• 眼科疾患治療薬市場、サブセグメント分析
  • 病院内薬局
  • 小売・オンライン薬局

第10章 眼科疾患治療薬の世界市場：地域別分析

• 眼科疾患治療薬市場、地域別市場スナップショット
• 北米
  • 米国
    • 薬剤クラス別の推定・予測、2019年～2029年
    • 投与量別の推定・予測、2019-2029年から
    • 疾患別適応症別の推定・予測、2019-2029年
    • 流通チャネル別の推定・予測、2019年～2029年
  • カナダ
• 欧州の眼科疾患治療薬市場スナップショット
  • 英国
  • ドイツ
  • フランス
  • スペイン
  • イタリア
  • その他欧州
• アジア太平洋の眼科疾患治療薬市場スナップショット
  • 中国
  • インド
  • 日本
  • オーストラリア
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカの眼科疾患治療薬市場スナップショット
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ地域
• 世界のその他の地域

第11章 競合情報

• 主要市場戦略
• 企業プロファイル
  • Viatris Inc.
    • 主要な情報
    • 概要
    • 財務（データの入手が可能な場合のみ）
    • 製品概要
    • 最近の動向
  • Novartis AG
  • AbbVie Inc.
  • F. Hoffmann-La Roche Ltd.
  • Regeneron Pharmaceuticals, Inc.
  • Santen Pharmaceutical Co., Ltd.
  • Bayer AG
  • Bausch & Lomb Incorporated
  • Merck KGaA
  • Nicox SA

第12章 調査プロセス

• 調査プロセス
  • データマイニング
  • 分析
  • 市場推定
  • バリデーション
  • 出版
• 調査の特徴
• 調査の前提条件

LIST OF TABLES

• TABLE 1. Global Ophthalmic Disease Therapeutics Market, report scope
• TABLE 2. Global Ophthalmic Disease Therapeutics Market estimates & forecasts by Region 2019-2029 (USD Billion)
• TABLE 3. Global Ophthalmic Disease Therapeutics Market estimates & forecasts by Drug Class 2019-2029 (USD Billion)
• TABLE 4. Global Ophthalmic Disease Therapeutics Market estimates & forecasts by Dosage From 2019-2029 (USD Billion)
• TABLE 5. Global Ophthalmic Disease Therapeutics Market estimates & forecasts by Disease Indication 2019-2029 (USD Billion)
• TABLE 6. Global Ophthalmic Disease Therapeutics Market estimates & forecasts by Distribution Channel 2019-2029 (USD Billion)
• TABLE 7. Global Ophthalmic Disease Therapeutics Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 8. Global Ophthalmic Disease Therapeutics Market by region, estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 9. Global Ophthalmic Disease Therapeutics Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 10. Global Ophthalmic Disease Therapeutics Market by region, estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 11. Global Ophthalmic Disease Therapeutics Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 12. Global Ophthalmic Disease Therapeutics Market by region, estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 13. Global Ophthalmic Disease Therapeutics Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 14. Global Ophthalmic Disease Therapeutics Market by region, estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 15. Global Ophthalmic Disease Therapeutics Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 16. Global Ophthalmic Disease Therapeutics Market by region, estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 17. U.S. Ophthalmic Disease Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 18. U.S. Ophthalmic Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 19. U.S. Ophthalmic Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 20. Canada Ophthalmic Disease Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 21. Canada Ophthalmic Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 22. Canada Ophthalmic Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 23. UK Ophthalmic Disease Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 24. UK Ophthalmic Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 25. UK Ophthalmic Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 26. Germany Ophthalmic Disease Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 27. Germany Ophthalmic Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 28. Germany Ophthalmic Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 29. France Ophthalmic Disease Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 30. France Ophthalmic Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 31. France Ophthalmic Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 32. Italy Ophthalmic Disease Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 33. Italy Ophthalmic Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 34. Italy Ophthalmic Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 35. Spain Ophthalmic Disease Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 36. Spain Ophthalmic Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 37. Spain Ophthalmic Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 38. RoE Ophthalmic Disease Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 39. RoE Ophthalmic Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 40. RoE Ophthalmic Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 41. China Ophthalmic Disease Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 42. China Ophthalmic Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 43. China Ophthalmic Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 44. India Ophthalmic Disease Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 45. India Ophthalmic Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 46. India Ophthalmic Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 47. Japan Ophthalmic Disease Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 48. Japan Ophthalmic Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 49. Japan Ophthalmic Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 50. South Korea Ophthalmic Disease Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 51. South Korea Ophthalmic Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 52. South Korea Ophthalmic Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 53. Australia Ophthalmic Disease Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 54. Australia Ophthalmic Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 55. Australia Ophthalmic Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 56. RoAPAC Ophthalmic Disease Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 57. RoAPAC Ophthalmic Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 58. RoAPAC Ophthalmic Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 59. Brazil Ophthalmic Disease Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 60. Brazil Ophthalmic Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 61. Brazil Ophthalmic Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 62. Mexico Ophthalmic Disease Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 63. Mexico Ophthalmic Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 64. Mexico Ophthalmic Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 65. RoLA Ophthalmic Disease Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 66. RoLA Ophthalmic Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 67. RoLA Ophthalmic Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 68. Row Ophthalmic Disease Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 69. Row Ophthalmic Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 70. Row Ophthalmic Disease Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 71. List of secondary sources, used in the study of global Ophthalmic Disease Therapeutics Market
• TABLE 72. List of primary sources, used in the study of global Ophthalmic Disease Therapeutics Market
• TABLE 73. Years considered for the study
• TABLE 74. Exchange rates considered

List of tables and figures and dummy in nature, final lists may vary in the final deliverable

LIST OF FIGURES

List of figures

• FIG 1. Global Ophthalmic Disease Therapeutics Market, research methodology
• FIG 2. Global Ophthalmic Disease Therapeutics Market, Market estimation techniques
• FIG 3. Global Market size estimates & forecast methods
• FIG 4. Global Ophthalmic Disease Therapeutics Market, key trends 2021
• FIG 5. Global Ophthalmic Disease Therapeutics Market, growth prospects 2022-2029
• FIG 6. Global Ophthalmic Disease Therapeutics Market, porters 5 force model
• FIG 7. Global Ophthalmic Disease Therapeutics Market, pest analysis
• FIG 8. Global Ophthalmic Disease Therapeutics Market, value chain analysis
• FIG 9. Global Ophthalmic Disease Therapeutics Market by segment, 2019 & 2029 (USD Billion)
• FIG 10. Global Ophthalmic Disease Therapeutics Market by segment, 2019 & 2029 (USD Billion)
• FIG 11. Global Ophthalmic Disease Therapeutics Market by segment, 2019 & 2029 (USD Billion)
• FIG 12. Global Ophthalmic Disease Therapeutics Market by segment, 2019 & 2029 (USD Billion)
• FIG 13. Global Ophthalmic Disease Therapeutics Market by segment, 2019 & 2029 (USD Billion)
• FIG 14. Global Ophthalmic Disease Therapeutics Market, regional snapshot 2019 & 2029
• FIG 15. North America Ophthalmic Disease Therapeutics Market 2019 & 2029 (USD Billion)
• FIG 16. Europe Ophthalmic Disease Therapeutics Market 2019 & 2029 (USD Billion)
• FIG 17. Asia pacific Ophthalmic Disease Therapeutics Market 2019 & 2029 (USD Billion)
• FIG 18. Latin America Ophthalmic Disease Therapeutics Market 2019 & 2029 (USD Billion)
• FIG 19. Global Ophthalmic Disease Therapeutics Market, company Market share analysis (2021)

List of tables and figures and dummy in nature, final lists may vary in the final deliverable

Global Ophthalmic Disease Therapeutics Market is valued at approximately USD 31.54 billion in 2021 and is anticipated to grow with a healthy growth rate of more than 6.4% over the forecast period 2022-2029. Drugs and therapies for treating various ocular ailments such as glaucoma, dry eye disease, retinal diseases, and others are included in ophthalmic disease therapeutics. The Ophthalmic Disease Therapeutics market is expanding because of factors such as the rising prevalence of ophthalmic conditions and increasing clinical trials and pipeline candidates for Innovative Drugs and Therapies.

Globally, the prevalence of ophthalmic diseases such as glaucoma, retinal diseases, dry eye disease, and others is on the rise which is catering for market growth. According to a 2020 article from the American Academy of Ophthalmology (AAO), 3.0 million Americans, of whom 2.7 million are 40 years of age or older, have glaucoma. According to the World Bank Group, the world's old population was 727 million in 2020, and it is predicted to treble over the next three decades, reaching 1.5 billion in 2050. The increasing number of initiatives taken by various healthcare organizations, governmental entities, and industry actors, there is a greater awareness among the public about ocular disorders, the market demand for treatments for ocular diseases is anticipated to be boosted by factors such as growing healthcare costs and an increase in the number of ophthalmologists in both developed and developing nations. According to the Welsh Government's 2021 report, The number of ophthalmic practitioners in Wales climbed to 961 in March 2021 from 885 in March 2020. However, the high cost of Ophthalmic Disease Therapeutics stifles market growth throughout the forecast period of 2022-2029.

The key regions considered for the Global Ophthalmic Disease Therapeutics Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America dominated the market in terms of revenue, owing to the increasing rates of diagnosis and treatment, as well as an increase in the prevalence of numerous ocular illnesses. Additionally, rising healthcare spending in the region supporting eye care and eye health, as well as acceptable compensation for a variety of ocular problems, encourage the region's major economies to adopt cutting-edge and novel treatments. Whereas Europe is expected to grow with the highest CAGR during the forecast period, owing to factors such as rising geriatric and target populations, an increase in the number of collaborations for product development, geographic expansion of key players, and active participation of government and nonprofit organizations in the market space.

Major market player included in this report are:

• Viatris Inc.
• Novartis AG
• AbbVie Inc.
• F. Hoffmann-La Roche Ltd.
• Regeneron Pharmaceuticals, Inc.
• Santen Pharmaceutical Co., Ltd.
• Bayer AG
• Bausch & Lomb Incorporated
• Merck KGaA
• Nicox SA

Recent Developments in the Market:

• In May 2022, Zhaoke Ophthalmology Limited and Visus Therapeutics, Inc. partnership to commercialize BRIMOCHOL PF and Carbachol PF in Greater China, South Korea, and a few other Southeast Asian countries. Visus Therapeutics, Inc. specializes in the development of ophthalmic therapies. Both of these eye drops lack preservatives and are intended to correct presbyopia-related vision problems.
• In March 2022, The European Commission has given Novartis AG clearance to market Beovu, an ophthalmic drug intended to treat diabetic macular edema-related vision loss.

Global Ophthalmic Disease Therapeutics Market Report Scope:

• Historical Data 2019-2020-2021
• Base Year for Estimation 2021
• Forecast period 2022-2029
• Report Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
• Segments Covered Drug Class, Dosage Form, Disease Indication, Distribution Channel, Region
• Regional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World
• Customization Scope Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and Drug Classofferings of key players. The detailed segments and sub-segment of the market are explained below.

By Drug Class:

• Anti-inflammatory
• Anti-invectives
• Anti-VEGF
• Others

By Dosage Form:

• Solid
• Liquid
• Semisolid

By Disease Indication:

• Glaucoma
• Dry Eye Disease
• Retinal Disease
• Allergy & Infections
• Others

By Distribution Channel:

• Hospital Pharmacies
• Retail & Online Pharmacies

By Region:

• North America
• U.S.
• Canada
• Europe
• UK
• Germany
• France
• Spain
• Italy
• ROE
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• RoAPAC
• Latin America
• Brazil
• Mexico
• RoLA
• Rest of the World

Table of Contents

Chapter 1. Executive Summary

• 1.1. Market Snapshot
• 1.2. Global & Segmental Market Estimates & Forecasts, 2019-2029 (USD Billion)
  • 1.2.1. Ophthalmic Disease Therapeutics Market, by Region, 2019-2029 (USD Billion)
  • 1.2.2. Ophthalmic Disease Therapeutics Market, by Drug Class, 2019-2029 (USD Billion)
  • 1.2.3. Ophthalmic Disease Therapeutics Market, by Dosage From, 2019-2029 (USD Billion)
  • 1.2.4. Ophthalmic Disease Therapeutics Market, by Disease Indication, 2019-2029 (USD Billion)
  • 1.2.5. Ophthalmic Disease Therapeutics Market, by Distribution Channel, 2019-2029 (USD Billion)
• 1.3. Key Trends
• 1.4. Estimation Methodology
• 1.5. Research Assumption

Chapter 2. Global Ophthalmic Disease Therapeutics Market Definition and Scope

• 2.1. Objective of the Study
• 2.2. Market Definition & Scope
  • 2.2.1. Scope of the Study
  • 2.2.2. Industry Evolution
• 2.3. Years Considered for the Study
• 2.4. Currency Conversion Rates

Chapter 3. Global Ophthalmic Disease Therapeutics Market Dynamics

• 3.1. Ophthalmic Disease Therapeutics Market Impact Analysis (2019-2029)
  • 3.1.1. Market Drivers
    • 3.1.1.1. Rising Prevalence of Ophthalmic Conditions
    • 3.1.1.2. Increasing Clinical Trials and Pipeline Candidates for Innovative Drugs and Therapies
  • 3.1.2. Market Challenges
    • 3.1.2.1. High Cost of Biologics and Overall Treatment Cost
  • 3.1.3. Market Opportunities
    • 3.1.3.1. Rising Technological Advancements in Drug Delivery Options
    • 3.1.3.2. Rising development of personalised medicine

Chapter 4. Global Ophthalmic Disease Therapeutics Market Industry Analysis

• 4.1. Porter's 5 Force Model
  • 4.1.1. Bargaining Power of Suppliers
  • 4.1.2. Bargaining Power of Buyers
  • 4.1.3. Threat of New Entrants
  • 4.1.4. Threat of Substitutes
  • 4.1.5. Competitive Rivalry
• 4.2. Futuristic Approach to Porter's 5 Force Model (2019-2029)
• 4.3. PEST Analysis
  • 4.3.1. Political
  • 4.3.2. Economical
  • 4.3.3. Social
  • 4.3.4. Technological
• 4.4. Top investment opportunity
• 4.5. Top winning strategies
• 4.6. Industry Experts Prospective
• 4.7. Analyst Recommendation & Conclusion

Chapter 5. Risk Assessment: COVID-19 Impact

• 5.1. Assessment of the overall impact of COVID-19 on the industry
• 5.2. Pre COVID-19 and post COVID-19 Market scenario

Chapter 6. Global Ophthalmic Disease Therapeutics Market, by Drug Class

• 6.1. Market Snapshot
• 6.2. Global Ophthalmic Disease Therapeutics Market by Drug Class, Performance - Potential Analysis
• 6.3. Global Ophthalmic Disease Therapeutics Market Estimates & Forecasts by Drug Class 2019-2029 (USD Billion)
• 6.4. Ophthalmic Disease Therapeutics Market, Sub Segment Analysis
  • 6.4.1. Anti-inflammatory
  • 6.4.2. Anti-invectives
  • 6.4.3. Anti-VEGF
  • 6.4.4. Others

Chapter 7. Global Ophthalmic Disease Therapeutics Market, by Dosage From

• 7.1. Market Snapshot
• 7.2. Global Ophthalmic Disease Therapeutics Market by Dosage From, Performance - Potential Analysis
• 7.3. Global Ophthalmic Disease Therapeutics Market Estimates & Forecasts by Dosage From 2019-2029 (USD Billion)
• 7.4. Ophthalmic Disease Therapeutics Market, Sub Segment Analysis
  • 7.4.1. Solid
  • 7.4.2. Liquid
  • 7.4.3. Semisolid

Chapter 8. Global Ophthalmic Disease Therapeutics Market, by Disease Indication

• 8.1. Market Snapshot
• 8.2. Global Ophthalmic Disease Therapeutics Market by Disease Indication, Performance - Potential Analysis
• 8.3. Global Ophthalmic Disease Therapeutics Market Estimates & Forecasts by Disease Indication 2019-2029 (USD Billion)
• 8.4. Ophthalmic Disease Therapeutics Market, Sub Segment Analysis
  • 8.4.1. Glaucoma
  • 8.4.2. Dry Eye Disease
  • 8.4.3. Retinal Disease
  • 8.4.4. Allergy & Infections
  • 8.4.5. Others

Chapter 9. Global Ophthalmic Disease Therapeutics Market, by Distribution Channel

• 9.1. Market Snapshot
• 9.2. Global Ophthalmic Disease Therapeutics Market by Distribution Channel, Performance - Potential Analysis
• 9.3. Global Ophthalmic Disease Therapeutics Market Estimates & Forecasts by Distribution Channel 2019-2029 (USD Billion)
• 9.4. Ophthalmic Disease Therapeutics Market, Sub Segment Analysis
  • 9.4.1. Hospital Pharmacies
  • 9.4.2. Retail & Online Pharmacies

Chapter 10. Global Ophthalmic Disease Therapeutics Market, Regional Analysis

• 10.1. Ophthalmic Disease Therapeutics Market, Regional Market Snapshot
• 10.2. North America Ophthalmic Disease Therapeutics Market
  • 10.2.1. U.S. Ophthalmic Disease Therapeutics Market
    • 10.2.1.1. Drug Class breakdown estimates & forecasts, 2019-2029
    • 10.2.1.2. Dosage From breakdown estimates & forecasts, 2019-2029
    • 10.2.1.3. Disease Indication breakdown estimates & forecasts, 2019-2029
    • 10.2.1.4. Distribution Channel breakdown estimates & forecasts, 2019-2029
  • 10.2.2. Canada Ophthalmic Disease Therapeutics Market
• 10.3. Europe Ophthalmic Disease Therapeutics Market Snapshot
  • 10.3.1. U.K. Ophthalmic Disease Therapeutics Market
  • 10.3.2. Germany Ophthalmic Disease Therapeutics Market
  • 10.3.3. France Ophthalmic Disease Therapeutics Market
  • 10.3.4. Spain Ophthalmic Disease Therapeutics Market
  • 10.3.5. Italy Ophthalmic Disease Therapeutics Market
  • 10.3.6. Rest of Europe Ophthalmic Disease Therapeutics Market
• 10.4. Asia-Pacific Ophthalmic Disease Therapeutics Market Snapshot
  • 10.4.1. China Ophthalmic Disease Therapeutics Market
  • 10.4.2. India Ophthalmic Disease Therapeutics Market
  • 10.4.3. Japan Ophthalmic Disease Therapeutics Market
  • 10.4.4. Australia Ophthalmic Disease Therapeutics Market
  • 10.4.5. South Korea Ophthalmic Disease Therapeutics Market
  • 10.4.6. Rest of Asia Pacific Ophthalmic Disease Therapeutics Market
• 10.5. Latin America Ophthalmic Disease Therapeutics Market Snapshot
  • 10.5.1. Brazil Ophthalmic Disease Therapeutics Market
  • 10.5.2. Mexico Ophthalmic Disease Therapeutics Market
  • 10.5.3. Rest of Latin America Ophthalmic Disease Therapeutics Market
• 10.6. Rest of The World Ophthalmic Disease Therapeutics Market

Chapter 11. Competitive Intelligence

• 11.1. Top Market Strategies
• 11.2. Company Profiles
  • 11.2.1. Viatris Inc.
    • 11.2.1.1. Key Information
    • 11.2.1.2. Overview
    • 11.2.1.3. Financial (Subject to Data Availability)
    • 11.2.1.4. Product Summary
    • 11.2.1.5. Recent Developments
  • 11.2.2. Novartis AG
  • 11.2.3. AbbVie Inc.
  • 11.2.4. F. Hoffmann-La Roche Ltd.
  • 11.2.5. Regeneron Pharmaceuticals, Inc.
  • 11.2.6. Santen Pharmaceutical Co., Ltd.
  • 11.2.7. Bayer AG
  • 11.2.8. Bausch & Lomb Incorporated
  • 11.2.9. Merck KGaA
  • 11.2.10. Nicox SA

Chapter 12. Research Process

• 12.1. Research Process
  • 12.1.1. Data Mining
  • 12.1.2. Analysis
  • 12.1.3. Market Estimation
  • 12.1.4. Validation
  • 12.1.5. Publishing
• 12.2. Research Attributes
• 12.3. Research Assumption